BNET Industries
Last Fiscal Year Sales:$1.2B
- Public
- US
Dow Jones Description
Founded in 1984, Sepracor was originally comprised of several diverse business units. In 1989, we embarked on a strategy of developing single isomers and active metabolites of many of the world's largest selling drugs, with the objective of developing our own proprietary pipeline of pharmaceutical products. Sepracor became a publicly traded corporation in 1991, and we subsequently divested our non-pharmaceutical business units into four different companies, retaining our core pharmaceutical business. Sepracor was built on the premise that chiral drugs could, in essence, be divided into two or more "parts" and that certain of these parts could be brought to the market as new medicines with the possibility for reduced side effects, greater potency or new indications. Sepracor was a pioneer in this area of drug development, identifying new, viable compounds. This strategy enabled Sepracor to establish itself initially by out-licensing the rights to a number of compounds to large, established pharmaceutical companies who developed and ultimately commercialized them. Some of these compounds have grown to become well-known brands in the pharmaceutical industry: ALLEGRA brand fexofenadine HCl, CLARINEX brand desloratadine and XYZAL /XUSALTM brand levocetirizine. ...
Number of Employees 2,400
Peer Companies
NAICS Code Pharmaceutical and Medicine Manufacturing: 3254
Recent Events
-
Sepracor CEO in line for $11M golden handshake
-
Data Missing On US Drug Labels
-
Sepracor deal closes, CEO in line for $11M
-
Standard & Poor's Announces Changes To U.S. Indices - Update
-
Levi & Korsinsky, LLP Announces Class Action Lawsuit Against Sepracor, Inc. -- SEPR
-
Sepracor investors try to derail $2.6B Dainippon buyout
-
Japanese Pharma on the Move Again With Lots of Acquisitions, Globalization
-
Dainippon Sumitomo to buy Sepracor
-
Dainippon Agrees to Buy Sepracor
-
Sepracor to Merge With Dainippon in $2.6 Billion Deal
-
Nikkei nudges down 0.2 pct, Daiwa and SMFG slip
-
Willkie Farr and Paul Weiss on $2.6 Billion Japanese Pharma Deal
-
Asian markets mixed as China soars while US data weighs
-
Sepracor Accepts $2.6 Billion Dainippon Bid
-
Stocks Await Service Sector Data To Break Lackluster Phase - RTTNews Daily Market Analysis
-
Japanese company to buy Sepracor for $2.6 billion
-
Dainippon to buy Sepracor
-
Dainippon Sumitomo Pharma to acquire Sepracor for $2.6 billion
News & Analysis
Filter by
sales force management and sepracor inc. - All News and Analysis
Sepracor Has Stopped Advertising Lunesta, But Sales Still Go Up
BNET
- 2009-09-15
Sepracor appears to have almost stopped advertising for sleeping pill Lunesta, and yet sales are still rising. Sepracor spent less than $1 million on ads for the brand in 2009, but Lunesta sales were up 2 percent to $151 million in Q2 2009. by Jim Edwards
Sepracor Q2: More Miracles From Marlborough
BNET
- 2009-07-24
Sepracor has once again achieved the impossible by growing sales of its sleeping pill Lunesta despite an almost infinite number of generic and OTC competitors. Lunesta sales were up 2 percent to $151 million in Q2 2009, the company reported. by Jim Edwards
Sepracor Inc. Q2 2009 Earnings Call Transcript
Seeking Alpha
- 2009-07-24
Question-and-Answer SessionOperator Thank you. Ladies and gentlemen the floor is now opened for questions. Operator instructions Our first question comes from the line of Chris Schott with JP Morgan. Please go ahead. Chris Schott – JP Morgan Great. Thanks. Just a couple of quick questions. May be to start...
Sepracor Inc. Q1 2009 Earnings Call Transcript
Seeking Alpha
- 2009-05-04
Question-and-Answer Session Operator Thank you, Mr. Adams. The floor is now open for questions. Operator Instructions. And our first question is coming from the line of Manoj Garg with Soleil Securities. Please go ahead, your line is open. Manoj Garg - Soleil Group Hey, good morning guys. I’ve...
Ranking of 20 Drug Companies' Sales Forces Shows Productivity Flat or Declining
BNET
- 2009-02-24
A ranking of drug company sales productivity shows Gilead gets the most revenues in return for every dollar invested in reps and marketing. At the other end of the table, Sepracor gets the least bang for its sales, general and administrative buck see table below. ...
Sepracor Announces 940 Layoffs; Achieves the Impossible on Lunesta Sales
BNET
- 2009-01-29
Back in August, BNET ragged on Sepracor for implementing a cost-cutting program that drove up its expenses and drove down its revenue. In its Q4 earnings today, the company has turned that all around -- sales are up and expenses are down. The turnaround has come at...
At Sepracor, a Cost-Cutting Exercise Proves Expensive
BNET
- 2008-08-13
Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 sales force positions." The company said it needed to make the layoffs because, by last October, its revenues were falling....
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Sepracor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
